neuropathic pain

Novartis International will acquire Spinifex Pharmaceuticals, a developer of drugs for chronic pain, for an upfront cash consideration of $200 million, plus undisclosed clinical development and regulatory milestone payments. Read more


AAH Pharma will continue the clinical development of a compound with the potential to treat neuropathic pain. Read more